Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.

@article{Dammacco2013TherapyFH,
  title={Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.},
  author={Franco Dammacco and Domenico Sansonno},
  journal={The New England journal of medicine},
  year={2013},
  volume={369 11},
  pages={
          1035-45
        }
}
  • Franco Dammacco, Domenico Sansonno
  • Published in
    The New England journal of…
    2013
  • Medicine
  • Cryoglobulins are present in about a quarter of patients with hepatitis C; in some, cryoglobulinemia can become symptomatic or even life-threatening. This review summarizes evolving therapy for the disorder, including new therapeutic options that are becoming available. 

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    10 patients with chronic genotype 1 HCV infection and mixed cryoglobulinemia will be treated with Ledipasvir/Sofosbuvir 90mg/400 mg FDC once daily for 12 weeks (naïve subjects or… Expand
    ConditionsCryoglobulinemia, Hepatitis C
    InterventionDrug

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 77 CITATIONS, ESTIMATED 39% COVERAGE

    JCS 2017 Guideline on Management of Vasculitis Syndrome - Digest Version.

    FILTER CITATIONS BY YEAR

    2014
    2020

    CITATION STATISTICS

    • 6 Highly Influenced Citations

    • Averaged 12 Citations per year from 2017 through 2019

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 90 REFERENCES

    Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible?